Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
January 28, 2021 08:05 ET
|
Aeterna Zentaris Inc
- Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis...
Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
January 26, 2021 16:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
January 05, 2021 08:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin
December 07, 2020 08:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmaceutical...
Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin
November 16, 2020 08:05 ET
|
Aeterna Zentaris Inc
- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02...
Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update
November 06, 2020 08:35 ET
|
Aeterna Zentaris Inc
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021 – Continue to advance discussions to secure a commercialization partner for macimorelin in...
Aeterna Zentaris Provides Corporate Update
September 16, 2020 08:05 ET
|
Aeterna Zentaris Inc
– Recently secured funding bolsters cash runway to fund operations and provides significant optionality for growth – Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to...
Aeterna Zentaris to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 09, 2020 08:00 ET
|
Aeterna Zentaris Inc
- Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16th at 11:00 AM EDT - CHARLESTON, S.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:...
Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology
September 08, 2020 08:05 ET
|
Aeterna Zentaris Inc
- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults - - Data from this study support the choice of 1.0 mg/kg dose of...
Aeterna Zentaris Reports Second Quarter 2020 Financial Results and Provides Business Update
August 06, 2020 08:35 ET
|
Aeterna Zentaris Inc
– Positive results from AEZS-130-P01 (“Study P01”) confirmed dosing regimen of macimorelin as a potential diagnostic for childhood-onset growth hormone deficiency – Safety and efficacy...